Lidak Pharm. [LDAKA] Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA]

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Analog Kid who wrote (441)	8/18/1997 11:00:00 PM
From: MCorbley	of 1115

The R&D expenses were $4.6 M, 7.7 M, and 3.1 M, respectively, for fiscal 1996, 1995 and 1994. However, I think that the potential market size is a more important indicator of value. In 1993, Lidak estimated that more than 50 million Americans suffer at least one outbreak of HSV-1 per year, resulting in a total of more than 100 million outbreaks. Since we're not talking about a life-threatening illness or a treatment with worrisome side effects and since "patients" should have the drug before outbreaks occur, it will be an easy drug to prescribe. Personally, I believe that everyone who has ever had a Herpes fever blister will be very interested in obtaining a topical cream which shows even a slight chance of effectiveness. (Just think of how many antibiotics are prescribed for colds and flus even though they have no effect against viruses). So the valuation of Lidak should depend on the potential market for Lidakol and the market is very large. Of course, the cost per application and the percentage which Lidak makes must still be considered. M.C.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next